Merck bets big on circular RNA, paying $150M and dangling $3.5B in biobucks to work with Orna

August 16, 2022 – Orna Therapeutics is in the money. Tuesday morning, the developer of fully engineered circular RNA therapies revealed a double dose of good news, simultaneously taking the lid off an alliance with Merck & Co. worth $150 million upfront and a $221 million series B financing.